Tissue transglutaminase-induced aggregation of alpha-synuclein: Implications for Lewy body formation in Parkinson's disease and dementia with Lewy bodies.
about
Physio-pathological roles of transglutaminase-catalyzed reactionsTransglutaminase 2 has opposing roles in the regulation of cellular functions as well as cell growth and deathPossible involvement of transglutaminase-catalyzed reactions in the physiopathology of neurodegenerative diseasesCellular functions of tissue transglutaminasePresence of tissue transglutaminase in granular endoplasmic reticulum is characteristic of melanized neurons in Parkinson's disease brainGliadin peptides induce tissue transglutaminase activation and ER-stress through Ca2+ mobilization in Caco-2 cellsAnti-aggregating effect of the naturally occurring dipeptide carnosine on aβ1-42 fibril formationRepression of alpha-synuclein expression and toxicity by microRNA-7.Tissue transglutaminase-mediated glutamine deamidation of beta-amyloid peptide increases peptide solubility, whereas enzymatic cross-linking and peptide fragmentation may serve as molecular triggers for rapid peptide aggregationMicroRNA-7 protects against 1-methyl-4-phenylpyridinium-induced cell death by targeting RelA.Aberrant calcium signaling by transglutaminase-mediated posttranslational modification of inositol 1,4,5-trisphosphate receptorsTransglutaminase 2 exacerbates α-synuclein toxicity in mice and yeastAnti-inflammatory effects of the R2 peptide, an inhibitor of transglutaminase 2, in a mouse model of allergic asthma, induced by ovalbumin.ER stress response plays an important role in aggregation of α-synucleinNeuropathology, biochemistry, and biophysics of alpha-synuclein aggregation.Advances in gene therapy for movement disorders.Alpha-synuclein function and dysfunction on cellular membranes.Proteasome inhibition induces α-synuclein SUMOylation and aggregate formation.Two isoforms of tissue transglutaminase mediate opposing cellular fates.Tissue transglutaminase in marmoset experimental multiple sclerosis: discrepancy between white and grey matter.Role of the deubiquitylating enzyme DmUsp5 in coupling ubiquitin equilibrium to development and apoptosis in Drosophila melanogaster.Interaction of α-synuclein with vesicles that mimic mitochondrial membranes.Parkinson's Protein α-Synuclein Binds Efficiently and with a Novel Conformation to Two Natural Membrane MimicsTransglutaminase 2 inhibitors and their therapeutic role in disease states.Pharmacokinetics of cysteamine bitartrate following gastrointestinal infusion.Tissue transglutaminase crosslinks ataxin-1: possible role in SCA1 pathogenesis.γ-Glutamylamines and neurodegenerative diseasesTransglutaminase 2 cross-linking activity is linked to invadopodia formation and cartilage breakdown in arthritis.Transglutaminase induces protofibril-like amyloid beta-protein assemblies that are protease-resistant and inhibit long-term potentiationThe Lewy body in Parkinson's disease: molecules implicated in the formation and degradation of alpha-synuclein aggregates.Physiological and pathological role of alpha-synuclein in Parkinson's disease through iron mediated oxidative stress; the role of a putative iron-responsive elementDissecting the mechanisms of tissue transglutaminase-induced cross-linking of alpha-synuclein: implications for the pathogenesis of Parkinson disease.Tissue transglutaminase, protein cross-linking and Alzheimer's disease: review and views.Transglutaminase activation in neurodegenerative diseases.Neurochemical approaches in the laboratory diagnosis of Parkinson and Parkinson dementia syndromes: a reviewTransglutaminase-mediated intramolecular cross-linking of membrane-bound alpha-synuclein promotes amyloid formation in Lewy bodies.Cause and consequence: mitochondrial dysfunction initiates and propagates neuronal dysfunction, neuronal death and behavioral abnormalities in age-associated neurodegenerative diseases.Endoplasmic reticulum stress activates transglutaminase 2 leading to protein aggregation.Potential of transglutaminase 2 as a therapeutic target.Parkinson's disease--the continuing search for biomarkers.
P2860
Q24605961-7493EB1C-EC37-4DF6-9509-27F3503D3797Q28069852-63CFCCCA-9CD7-45B0-A08C-31F997B55412Q28248796-AD454B04-567A-43A5-8D6C-54CE2E310259Q28260600-A42FD2F8-A4B0-4DD9-94E0-9E35C6515D95Q28291271-7BC469F1-5610-4482-9570-E5E56513C0D5Q28484010-B8204F79-EC54-40C5-8321-36D7AAE24522Q28534489-C9567ED5-B378-4540-A80D-3E6166A85ACAQ29542272-20793E3E-B3E8-4813-AED9-3181846BDED9Q33814180-FD8C2430-767D-4A6E-814E-52F563492BD1Q34197681-1607C887-25C0-4599-8085-DD3165EFD029Q34281322-E5AF831A-96EE-4A81-B5E9-4F05B4C10C01Q34365610-C575B354-4019-44FE-BB35-D9275C67C37CQ34449739-228649FD-01D9-485E-A198-36918CD3D2BBQ34468291-77629C46-3014-4B25-9FFF-D5FF44332360Q34648491-C333A639-85BD-4161-A9FD-8E8C8BB9A1CCQ34656049-D4A8E407-230D-4CEC-959F-0C2C73173BC2Q34774324-A62C39C0-72D6-484E-B5F2-5AE16F037F7AQ35085788-EB677E42-A066-4E22-B47B-FD7455E81C60Q35157424-73E72AA2-87EE-4C49-8CA9-F48A9CBCEF65Q35193921-EF5EDDB2-002E-4BE7-88B5-9D3A9087B086Q35217012-0B3D8ADD-39AC-44A9-904E-250315B8598AQ35740225-E2C7EB25-7327-45C4-9D99-B303BA3F83E5Q35847200-EDCF8C3E-E33C-4275-A8FA-3F08CD21C30FQ35989247-8BFCADAB-4687-4637-9021-FBF3FF168452Q36024965-81B55ED7-9C65-4921-9E66-541E2B8A33B4Q36227615-7F8A812D-0717-438E-8CD8-3722D68862F5Q36377238-F013EA1B-4326-4887-8C53-5AAD2264AE8EQ36633284-539852CD-3B0B-4420-A7E6-2E38955705D6Q36711191-A57EEEDC-FCF8-4A1F-91FC-58DC1A4DC25EQ37003482-5681D569-3C6B-4A99-A1A4-5D97B3BD9DF8Q37166339-7E0222F6-7F0B-4363-9505-E9474609403EQ37176469-E495C70A-4503-4A6E-965E-CB9EE77A4C59Q37266151-A1D5199B-D824-4BB8-987F-F56A848A84D4Q37352964-685C99F2-2515-47CF-9799-9617F6BCBD73Q37418238-64C3CC7B-9560-40A1-A972-0E98DE3FC37AQ37447970-3BF3AECD-FA4E-4009-8B47-FB789823DBA9Q37466088-ADBC15C2-0DFF-49CA-99AC-5729A5F536B9Q37685405-813AFC5A-3D0D-47BB-BE51-BF06E48B7D0CQ37776508-37C8BE9F-69F3-459D-946F-17618AFD1554Q37834648-9691BB2C-0DF0-4CA2-973A-135BDF80CC45
P2860
Tissue transglutaminase-induced aggregation of alpha-synuclein: Implications for Lewy body formation in Parkinson's disease and dementia with Lewy bodies.
description
2003 nî lūn-bûn
@nan
2003 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Tissue transglutaminase-induce ...... and dementia with Lewy bodies.
@ast
Tissue transglutaminase-induce ...... and dementia with Lewy bodies.
@en
Tissue transglutaminase-induce ...... and dementia with Lewy bodies.
@nl
type
label
Tissue transglutaminase-induce ...... and dementia with Lewy bodies.
@ast
Tissue transglutaminase-induce ...... and dementia with Lewy bodies.
@en
Tissue transglutaminase-induce ...... and dementia with Lewy bodies.
@nl
prefLabel
Tissue transglutaminase-induce ...... and dementia with Lewy bodies.
@ast
Tissue transglutaminase-induce ...... and dementia with Lewy bodies.
@en
Tissue transglutaminase-induce ...... and dementia with Lewy bodies.
@nl
P2093
P2860
P921
P356
P1476
Tissue transglutaminase-induce ...... and dementia with Lewy bodies.
@en
P2093
Eunsung Junn
M Maral Mouradian
Martha M Quezado
Ruben D Ronchetti
Soo-Youl Kim
P2860
P304
P356
10.1073/PNAS.0438021100
P407
P577
2003-02-07T00:00:00Z